Abstract: Drugs used for focal segmental glomerulosclerosis (FSGS) are limited.It is in need to explore new drugs.Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) in podocyte has been confirmed to be an important pathway leading to podocyte injury of FSGS.mTORC1 inhibitors such as rapamycin can alleviate FSGS lesions by inhibiting hyperactivation of mTORC1 in podocyte theoretically and have been used in clinical trials of patients with FSGS.However,the nephrotoxicity in some patients limits its further use.The progress in studies on mTORC1 inhibitors in FSGS is reviewed in this article.

Key words: focal segmental glomerulosclerosis, mammalian target of rapamycin complex 1, Rapamycin